Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Pembrolizumab
Keytruda
Not routinely available
SMC (SMC2683)
07/08/2024
Indication
In combination with gemcitabine and cisplatin for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma in adults.
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Not routinely available as not recommended for use in NHSScotland
Formulation
Concentrate for solution for infusion
Comments
Link to Advice
Advice Published
10/06/2024
SMC Submission Type
Non submission
SMC Status
Not recommended